Citius Pharma Amends $3.8M Note with Sub; Adds Equity Conversion

Citius Pharmaceuticals, Inc. amended a $3.8 million promissory note with its majority-owned subsidiary, Citius Oncology, Inc., in connection with Citius Oncology's new equity financing and debt facility. The amendment aligns the note's maturity with Citius Oncology's senior debt, making the principal payable 91 days after the senior debt is fully settled. It also introduces a voluntary conversion feature, allowing Citius Pharmaceuticals to convert the outstanding principal into Citius Oncology common stock at $0.90 per share, subject to approval. Additionally, the amendment eliminates prior maturity triggers and prohibits cash prepayments before the new maturity date.